AUTHOR=Huang Xinru , Zhang Ting , Li Bin , Meng Yahui , Li Fen 

TITLE=Research on comorbidity characteristics and patterns of hospitalized participants with schizophrenia in China

JOURNAL=Frontiers in Psychiatry

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1619051

DOI=10.3389/fpsyt.2025.1619051

ISSN=1664-0640

ABSTRACT=IntroductionParticipants with schizophrenia face the dual impacts of mental illness and physical diseases, which significantly affect their clinical prognosis and quality of life.MethodsThis study, which is based on multivariate clinical data, using data-driven approaches (statistical analysis and data mining techniques) to systematically characterize the comorbidities landscape of schizophrenia patients identifying key patterns and clinical profiles to inform optimized treatment strategies and health management interventions.ResultsIt was found that the comorbidity rate among hospitalized schizophrenia participants is notably high in China. Notably, significant variations in comorbidity profiles were identified across diverse demographic and clinical variables, including age, occupational status, marital status, duration of hospital stay, frequency of hospitalizations, and health insurance status. The comorbidities in schizophrenia participants primarily include acute upper respiratory infections (J00-J06), metabolic disorders (E70-E90), hypertension (I10-I15), and diabetes (E1 0-E14). Furthermore, four strongly associated comorbidities patterns were identified: the metabolic-cardiovascular comorbidities cluster, the co-disease cluster of respiratory system infection, gut respiratory symptom cluster, electrolyte imbalance infection trigger cluster were identified.DiscussionThe exploration of comorbidity characteristics and patterns in schizophrenia provides a quantifiable tool for enhancing treatment and health management outcomes for participants while also offering a reference for advancing the application of precision medicine in the treatment and management of schizophrenia.